Key result
Amyloid and tau biomarkers become increasingly abnormal from subjective cognitive impairment to Alzheimer's disease and may help identify individuals who will cognitively decline.
Why the study?
Can amyloid and tau biomarkers differentiate individuals with subjective cognitive impairment from healthy controls or predict cognitive decline?
Population
Individuals with subjective cognitive impairment (SCI)
Comparison
Amyloid and tau biomarkers vs Healthy controls
Design
Review
Authors
Loading...
May aid risk stratification in subjective cognitive impairment but should not yet change practice; leaves open need for prospective validation.
Can amyloid and tau biomarkers differentiate individuals with subjective cognitive impairment from healthy controls or predict cognitive decline?
Amyloid and tau biomarkers may help identify individuals with subjective cognitive impairment who are at risk for future cognitive decline, though they cannot differentiate SCI from healthy controls.
Colijn et al. (2015) conducted a review in Subjective cognitive impairment (SCI). Amyloid and tau biomarkers vs. Healthy controls was evaluated. Amyloid and tau biomarkers become increasingly abnormal from subjective cognitive impairment to Alzheimer's disease and may help identify individuals who will cognitively decline.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: